Clinical Trial Search

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 participants

Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) by Visit - Study Eye — 23.7; 25.7; 27.6; 41.5 letters

Primary: Unbound AUC(0-last): Unbound Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Ixazomib — 9.6476; 7.3292…

Primary: Percent Change From Baseline in Hepatic Fat — -35.73; -18.04; 8.63 Percent change — p=<0.001

Primary: Percentage of Patients With Complete or Partial Response as Measured by Change in Lesion Severity Using CAILS (Composite Assessment of Index Lesion Severity) — 27; 0…

Primary: Number of Participants Who Experienced a Dose Limiting Toxicity to Determine the Maximum Tolerated Dose (MTD) — 0; 2; 2 participants

Primary: Percentage of Subjects With Drug-related Adverse Events — 6.7; 0.0; 0.0; 0.0 percentage of participants

Primary: Steady State Area Under the Plasma Concentration Versus Time Curve From 0 to 12 Hours After Dosing (AUC0-12) of Oseltamivir and Oseltamivir Carboxylate — 5.092; 5.070…

Primary: AUC0-infinity of Plasma Deleobuvir — 19300 nmol*h/L

Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 1; 6; 1; 0 participants

Primary: Maximum Tolerated Dose (MTD) of Capecitabine. — 650 milligrams

Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) — 1; 12 participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 2; 0 Participants

Primary: Participants With Adverse Events by Treatment. — 8; 2 participants — p=0.01

Primary: Maximum Tolerated Dose (MTD) of RENCA Macrobeads — NA RENCA Macrobeads/kg